Pirfenidone (high and low dose) 	Placebo	Vital capacity (after 3 months)	14240	14377	Significant differences were also seen between high- and low- dose pirfenidone and placebo groups (p = 0.0064, 0.0381, 0.0091, and 0.0010
Pirfenidone (high and low dose) 	Placebo	Vital capacity (after 3 months)	14240	14462	Significant differences were also seen between high- and low- dose pirfenidone and placebo groups (p = 0.0064, 0.0381, 0.0091, and 0.0010, Risk ratio; 0.561, 0.652, 0.674, and 0.642 at months 3, 6, 9, and 12, respectively)
Pirfenidone (high and low dose) 	Placebo	Vital capacity (after 12 months)	14240	14377	Significant differences were also seen between high- and low- dose pirfenidone and placebo groups (p = 0.0064, 0.0381, 0.0091, and 0.0010
Pirfenidone (high and low dose) 	Placebo	Vital capacity (after 12 months)	14240	14464	Significant differences were also seen between high- and low- dose pirfenidone and placebo groups (p = 0.0064, 0.0381, 0.0091, and 0.0010, Risk ratio; 0.561, 0.652, 0.674, and 0.642 at months 3, 6, 9, and 12, respectively) (
Pirfenidone (high-dose) 	Placebo	Vital capacity (after 3 months)	13965	14140	Significant differences in the distributions of the ratings were consistently observed between high-dose pirfenidone and placebo groups (p = 0.0136, 0.0447, 0.0166, and 0.0053
Pirfenidone (low-dose) 	Placebo	Vital capacity (after 3 months)	14240	14528	Significant differences were also seen between high- and low- dose pirfenidone and placebo groups (p = 0.0064, 0.0381, 0.0091, and 0.0010, Risk ratio; 0.561, 0.652, 0.674, and 0.642 at months 3, 6, 9, and 12, respectively) (Figure 1-b), and between low-dose pirfenidone and placebo groups
Pirfenidone (high and low dose) 	Placebo	Vital capacity (after 3 months)	13965	14225	Significant differences in the distributions of the ratings were consistently observed between high-dose pirfenidone and placebo groups (p = 0.0136, 0.0447, 0.0166, and 0.0053, Risk ratio; 0.578, 0.640, 0.671, and 0.665 at months 3, 6, 9, and 12, respectively)
Pirfenidone (high-dose) 	Placebo	Vital capacity (after 3 months)	13963	14225	. Significant differences in the distributions of the ratings were consistently observed between high-dose pirfenidone and placebo groups (p = 0.0136, 0.0447, 0.0166, and 0.0053, Risk ratio; 0.578, 0.640, 0.671, and 0.665 at months 3, 6, 9, and 12, respectively)
Pirfenidone (high-dose) 	Placebo	Vital capacity (after 12 months)	13965	14140	Significant differences in the distributions of the ratings were consistently observed between high-dose pirfenidone and placebo groups (p = 0.0136, 0.0447, 0.0166, and 0.0053
